Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany

nCounter® Analysis System


Prosigna is powered by the best-in-class nCounter® Analysis System

Now, local qualified laboratories can generate precise gene expression profiling1.

  • Strong analytical performance: sensitive, precise, and quantitative
  • Single-tube multiplexing: all 50 Prosigna genes are measured in a single reaction – no amplification required
  • Easy to use, fully automated, intuitive user interface
  • Requires minimal hands-on time

1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.